Abstract 81P
Background
Limited infiltration and exhaustion of transferred T cells are key factors impeding the development of adoptive cell immunotherapy in solid tumors. Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. A tumor-penetrating peptide iRGD modified T cells (SmarT cells) were established to promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells.
Results
We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 10 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection. Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated solid cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The legal committee of Nanjing Drumtower Hospital.
Funding
The funds for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (No. 2022-LCYJ-ZD-05, B.L.).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract